![]() It is unclear what role n-3 PUFAs play in stroke and whether they have a beneficial effect on stroke recovery and prognosis. N-3 PUFAs can reduce blood lipid levels and can significantly improve endothelial dysfunction ( 11- 13). ![]() Among the many risk factors for cardiovascular and cerebrovascular diseases, abnormal blood lipid levels and lipid metabolism disorders play an important role ( 10). N-3 polyunsaturated fatty acids (n-3 PUFAs) have various pharmacological activities, such as anti-inflammatory, anti-thrombosis, and anti-atherosclerosis activities ( 6- 9). Hence, we need to explore novel treatments for stroke ( 4, 5). Due to the aging of the population and insufficient management of risk factors, this burden is expected to be further increased. ![]() The increasing number of strokes has caused a substantial burden for patients, their families, and society. The mortality and morbidity of stroke have decreased in recent years, but stroke remains the second leading cause of death and disability worldwide ( 2, 3). Stroke is associated with multiple serious complications, such as pulmonary infection and deep venous thrombosis (DVT), and is also often accompanied by motor disorders, swallowing disorders, sensory disorders, and other sequelae. In addition to drug treatment, nutrient support is also an important approach for treating hemorrhagic stroke. Treatment strategies for stroke vary based on its etiology, and the main methods for treating ischemic stroke include thrombolysis, mechanical thrombectomy, anti-platelet aggregation, reducing blood lipid levels, and promoting the recovery of neurological function. The incidence rate of ischemic stroke is approximately 2-3 times higher than that of hemorrhagic stroke ( 1). According to its etiology, stroke can be divided into ischemic stroke, hemorrhagic stroke, and other types of stroke. Stroke is a common acute cerebrovascular disease. A total of 18 RCTs were included, and the meta-analysis showed no differences in vascular disease-related death between the n-3 PUFA and control groups (RR, 0.95, 95 % CI: 0.89 to 1.01, p = 0.114 > 0.05).
0 Comments
Leave a Reply. |